CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Endpoints News
Original article

Erasca's $550M offering; Summit sells an antibiotic

LeqembiNeutral
AI Analysis

Summary

Erasca launched a $550M public offering to fund KRAS drug development. Summit is divesting an antibiotic asset.

Importance:5/10
Sentiment:
0.00
capital_raiseKRASbiotechofferingantibiotic
Related Companies

Read the original article

Published by Endpoints News on July 14, 2026 3:09 PM

Read Original